Cost Calculator Repinex External 2019-02-20T10:57:24+00:00

Enter the number of patients you wish to switch, to see the savings available from Repinex XL (ropinirole prolonged release tablets). Or alternatively, enter your Rx spend on generic ropinirole XL tablets, to see the savings available when you brand by Repinex XL (ropinirole XL prolonged released tablets).

Back to the Repinex XL Website

Savings based on patient numbers

Enter the number of patients to switch Ropinirole XL tablets Drug Tariff Price tablets (28)1 Repinex XL tablets (28) Cost Saving for switch to Repinex XL1* % Saving for switch to Repinex XL
2mg 50%
4mg 50%
8mg 50%
      Total Month Saving
Total Patients       Total Year Saving

Or savings based on prescribing spend

Enter a generic XL tablet prescribing spend Ropinirole XL tablets Cost Saving for switch to Repinex XL1* % Saving for switch to Repinex XL
2mg 50%
4mg 50%
8mg 50%
  Total Cost Saving

TOTALS

Total Patients you entered
Total Savings for the patients you entered (month)
Total Savings for the patients you entered (year)
Total Prescribing Cost Savings based on your entered costs

*50% saving on the cost of Category C ropinirole prolonged-release tablets in the UK Drug Tariff
Reference
1. January 2019 UK Drug Tariff

Further information at www.repinex.co.uk

Repinex XL (Ropinirole) Prolonged-Release Tablets (please refer to the full SmPC before prescribing)

Indications: Initial treatment in adults of Parkinson’s disease as monotherapy to delay the introduction of levodopa or in combination with levodopa, over the course of the disease, when levodopa effect wears off or becomes inconsistent and fluctuations in therapeutic effect occur. Available strengths: Repinex XL (ropinirole) 2, 4, and 8mg x 28 tablets. Dosage and method of use: Tablets to be taken once daily, at similar time each day, with or without food, and swallowed whole. Starting dose is 2mg once daily for first week, then increased to 4mg once daily from the second week of treatment. If symptomatic control not achieved, daily dose may be increased by 2mg at weekly or longer intervals up to 8mg once daily; if symptomatic control still not achieved, daily dose may be increased by 2-4mg at 2 weekly or longer intervals. Maximum daily dose is 24mg. Patients should be maintained on the lowest dose that achieves symptomatic control. When given as adjunct to levodopa, may be able to gradually reduce levodopa dose, depending on response. In advanced Parkinson’s Disease patients taking Repinex XL tablets in combination with levodopa, dyskinesias can occur during initial titration of Repinex XL tablets. In clinical trials, a reduction in levodopa dose was shown to potentially ameliorate dyskinesia. If treatment interrupted for one day or more, consider re-initiation by dose titration on ropinirole immediate-release tablets. Discontinue ropinirole treatment gradually over one week. In end stage renal disease where on haemodialysis, recommended initial dose 2mg once daily. Escalate dose according to tolerability and efficacy. Recommended maximum dose 18mg/day. Consider slower titration in patients aged 75 years or older. Contraindications: Hypersensitivity to active substance or excipients; severe renal impairment (creatinine clearance <30 ml/min) without regular haemodialysis; hepatic impairment. Special warnings and precautions for use: Inform patients that ropinirole is associated with somnolence and episodes of sudden sleep onset during daily activities, particularly in Parkinson’s disease. Advise caution while driving or operating machines.  If have experienced somnolence and/or an episode of sudden sleep onset, must refrain from driving or operating machines and consider dose reduction or termination. Due to risk of hypotension, blood pressure monitoring recommended, especially at start of treatment, in patients with severe cardiovascular disease (especially coronary insufficiency). If history of major psychotic disorders, only treat with dopamine agonists if benefits outweigh risks. Regularly monitor for development of impulse control disorders, including pathological gambling, increased libido, hypersexuality, compulsive spending/buying, binge or compulsive eating and if symptoms develop, consider dose reduction/tapered discontinuation. If rapid gastrointestinal transit, risk of incomplete release of active substance and residue being passed in the stool. Symptoms suggestive of neuroleptic malignant syndrome have been reported with abrupt withdrawal of dopaminergic therapy – therefore recommend tapering treatment. Dopamine agonist withdrawal syndrome: Inform patients that non-motor adverse effects may occur when tapering or discontinuing dopamine agonists including ropinirole. Symptoms include apathy, anxiety, depression, fatigue, sweating and pain which may be severe – monitor regularly. If persistent symptoms, consider increasing the ropinirole dose temporarily. Inform patients that hallucinations can occur.

Repinex XL 2mg contains lactose – not to be used in patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. Repinex XL 4mg contains sunset yellow (E110) – may cause allergic reactions in patients with sunset yellow sensitivity. Interactions: Concomitant treatment with neuroleptics and other centrally active dopamine antagonists e.g. sulpiride or metoclopramide, should be avoided. Increased ropinirole plasma concentrations observed in patients treated with high doses of oestrogens – if hormone replacement therapy is stopped or introduced during treatment with ropinirole it may be necessary to adjust the ropinirole dose. Ropinirole principally metabolised by CYP1A2 – in patients on ropinirole, dose may need to be adjusted when medicines known to inhibit CYP1A2, e.g., ciprofloxacin, enoxacin, cimetidine or fluvoxamine, are introduced or withdrawn. Smoking induces CYP1A2 metabolism – if patients stop or start smoking during treatment with Repinex XL, dose adjustment may be required. Pregnancy and lactation: Repinex XL not recommended during pregnancy and should not be used during lactation. Not recommended for children below 18 years of age. Ability to drive:  May have major effect on ability to drive/use machines. Refrain from driving/using machines if presenting with somnolence or sudden sleep episodes. Side effects: When Repinex XL is used as a monotherapy, side effects include: Very Common (≥1/10): somnolence, syncope, nausea; Common (≥1/100 to <1/10): dizziness (including vertigo), sudden onset of sleep, hallucinations, constipation, vomiting, heartburn, abdominal pain, peripheral oedema, leg oedema; Uncommon (≥1/1,000 to <1/100): excessive daytime somnolence, psychotic reactions (other than hallucinations) including delirium, delusion, paranoia, postural hypotension, hypotension; Not known (cannot be estimated from the available data): Impulse control disorders e.g. pathological gambling, increased libido, hypersexuality, compulsive shopping, binge eating, aggression, hypersensitivity reactions (including urticaria, angioedema, rash, pruritus), hepatic reactions, mainly increased liver enzymes, dopamine dysregulation syndrome, dopamine agonist withdrawal syndrome When Repinex XL is used as an adjunct therapy, side effects include: Very Common (>1/10): dyskinesia, somnolence, nausea; Common (≥1/100 to <1/10): dizziness (including vertigo), somnolence, sudden onset of sleep, hallucinations, confusion, postural hypotension, hypotension, heartburn, nausea, constipation, peripheral oedema; Uncommon (≥1/1,000 to <1/100): excessive daytime somnolence, psychotic reactions (other than hallucinations) including delirium, delusion, paranoia, postural hypotension, hypotension; Not known (cannot be estimated from the available data): Impulse control disorders e.g. pathological gambling, increased libido, hypersexuality, compulsive shopping, binge eating,  hypersensitivity reactions (including urticaria, angioedema, rash, pruritus), hepatic reactions, mainly increased liver enzymes, dopamine agonist withdrawal syndrome. MA number: PL 35533/0023-0025. Cost: £6.20 for 2mg x 28 pack, £12.50 for 4mg x 28 pack, £21.00 for 8mg x 28 pack. MAH: Aspire Pharma Limited, Unit 4 Rotherbrook Court, Bedford Road, Petersfield, Hampshire, GU32 3QG, United Kingdom. Legal Category: POM. Date last reviewed: January 2019. Version number: 1010112063 V 8.0.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148. 1010112336 v 3.0 January 2019